The statistical approach in trial-based economic evaluations matters: get your statistics together!

被引:27
作者
Mutubuki, Elizabeth N. [1 ,2 ]
El Alili, Mohamed [3 ]
Bosmans, Judith E. [3 ]
Oosterhuis, Teddy [3 ]
J. Snoek, Frank [4 ]
Ostelo, Raymond W. J. G. [1 ,2 ]
van Tulder, Maurits W. [5 ,6 ]
van Dongen, Johanna M. [1 ,3 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam Movement Sci Res Inst, Dept Hlth Sci, Fac Sci, Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Amsterdam Movement Sci Res Inst, Amsterdam UMC, Dept Epidemiol & Biostat, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Hlth Sci, Fac Sci, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Amsterdam UMC, Dept Med Psychol, Amsterdam, Netherlands
[5] Aarhus Univ Hosp, Dept Physiotherapy & Occupat Therapy, Aarhus, Denmark
[6] Vrije Univ Amsterdam, Fac Behav & Movement Sci, Dept Human Movement Sci, Amsterdam, Netherlands
关键词
Cost-benefit analysis; Statistical methods; Clinical trial; Missing data; Skewed data; Baseline imbalances; COST-EFFECTIVENESS ANALYSIS; CLUSTER RANDOMIZED-TRIALS; NET BENEFIT REGRESSION; HANDLING MISSING DATA; MULTIPLE IMPUTATION; PROBLEMATIC HYPOGLYCEMIA; CLINICAL-TRIALS; COVARIATE ADJUSTMENT; SUBGROUP ANALYSIS; INTERVENTION;
D O I
10.1186/s12913-021-06513-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Baseline imbalances, skewed costs, the correlation between costs and effects, and missing data are statistical challenges that are often not adequately accounted for in the analysis of cost-effectiveness data. This study aims to illustrate the impact of accounting for these statistical challenges in trial-based economic evaluations. Methods Data from two trial-based economic evaluations, the REALISE and HypoAware studies, were used. In total, 14 full cost-effectiveness analyses were performed per study, in which the four statistical challenges in trial-based economic evaluations were taken into account step-by-step. Statistical approaches were compared in terms of the resulting cost and effect differences, ICERs, and probabilities of cost-effectiveness. Results In the REALISE study and HypoAware study, the ICER ranged from 636,744euro/QALY and 90,989euro/QALY when ignoring all statistical challenges to - 7502euro/QALY and 46,592euro/QALY when accounting for all statistical challenges, respectively. The probabilities of the intervention being cost-effective at 0euro/ QALY gained were 0.67 and 0.59 when ignoring all statistical challenges, and 0.54 and 0.27 when all of the statistical challenges were taken into account for the REALISE study and HypoAware study, respectively. Conclusions Not accounting for baseline imbalances, skewed costs, correlated costs and effects, and missing data in trial-based economic evaluations may notably impact results. Therefore, when conducting trial-based economic evaluations, it is important to align the statistical approach with the identified statistical challenges in cost-effectiveness data. To facilitate researchers in handling statistical challenges in trial-based economic evaluations, software code is provided.
引用
收藏
页数:12
相关论文
共 82 条
  • [1] How well are randomized controlled trials reported in the dermatology literature?
    Adetugbo, K
    Williams, H
    [J]. ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 381 - 385
  • [2] Al MJ, 2000, HEALTH ECON, V9, P599
  • [3] [Anonymous], 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696
  • [4] [Anonymous], 2015, METHODS EC EVALUATI
  • [5] BAYESIAN MODELS FOR COST-EFFECTIVENESS ANALYSIS IN THE PRESENCE OF STRUCTURAL ZERO COSTS
    Baio, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A584 - A584
  • [6] Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO
  • [7] 2-P
  • [8] Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249
  • [9] What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?
    Barbieri, Marco
    Drummond, Michael
    Rutten, Frans
    Cook, John
    Glick, Henry A.
    Lis, Joanna
    Reed, Shelby D.
    Sculpher, Mark
    Severens, Johan L.
    [J]. VALUE IN HEALTH, 2010, 13 (08) : 1028 - 1037
  • [10] Missing .... presumed at random: cost-analysis of incomplete data
    Briggs, A
    Clark, T
    Wolstenholme, J
    Clarke, P
    [J]. HEALTH ECONOMICS, 2003, 12 (05) : 377 - 392